Results 21 to 30 of about 145 (144)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Когнитивниот дефицит кај возраÑни пациенти по анеÑтезија во не–кардијалната хирургија [PDF]

open access: yes, 2017
Studies of the early 21st century indicate that the decline in cognitive functionis as a complication of anesthesia and operative intervention. Whether there would be changes and the amount of changes in mental status will cause a type of anesthesia is a
Трајкова, Радмила   +2 more
core   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

open access: yesMolecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy   +9 more
wiley   +1 more source

ЕФЕКТИ ÐÐ CYP3A4 ГЕÐЕТСКИ ПОЛИМОРФИЗÐМ ВРЗ ПОСТОПЕРÐТИВÐÐТРПОТРОШУВÐЧКРÐРФЕÐТÐÐИЛ ПРИ ТРЕТМÐÐ ÐРПОСТОПЕРÐТИВÐÐТРБОЛКР[PDF]

open access: yes, 2017
Минималната ефективна концентрација на опиоиден аналгетик може значајно да Ñе разликува меѓу пациентите.
СпировÑка, Татјана   +8 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Животниот Ñтил и контрола на хроничните незаразни болеÑти [PDF]

open access: yes, 2018
Non-communicable diseases, also known as modern-life diseases, are the leading cause of morbidity and mortality in the world and in the Republic of Macedonia. The complexity of their occurrence, often associated with multifactorial etiology and lifestyle
СпаÑовÑки (Spasovski), Моме (Mome)   +3 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Верификација на квалитативни методи Ñо теÑÑ‚ ленти за иÑпитување на дроги кои Ñе злоупотребуваат во урина [PDF]

open access: yes, 2018
The verification of the  qualitative method with test  devices for detection of eight drugs of abuse in urine  (amphetamines, methamphetamine,  barbiturates,  benzoylecgonine,  marijuana, 3,4-methylendioxy-methamphetamine, methadone, and opiates) was ...
ТопузовÑка (Topuzovska), Соња (Sonja)   +4 more
core   +1 more source

Kвантитативно одредување на калпротектин во асцит кај пациенти со спонтан бактериски перитонитис

open access: yes, 2020
Спонтаниот бактериски перитонитис (СБП) кај пациентите со црнодробна цироза е новонастаната, спонтана бактериска инфекција на стерилна ас
Emilija Petrovska   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy